Prenetics (PRE) Q4 2025 earnings review
The Pivot Worked: IM8 Rockets to $120M ARR
Prenetics has successfully executed one of the most aggressive strategic pivots in recent memory. Revenue surged 457% YoY to $36.6M, driven entirely by its new consumer health brand, IM8, which went from zero to $120M Annualized Recurring Revenue (ARR) in 12 months. The company has aggressively cleaned house—divesting ACT Genomics, Europa, and Insighta—to amass a $171M war chest (including crypto) to fuel this growth. While still loss-making ($(28.4)M Net Loss), the unit economics appear robust with a <4 month payback period.
🐂 Bull Case
IM8 is not just growing; it is exploding. Monthly revenue hit $10M in December (+51% vs September). FY26 guidance ($180-200M) implies another doubling of the business.
Despite high growth, efficiency is holding. Payback period dropped to 3.5 months (from 3.9), and LTV:CAC ratio is ~3x. The shift to quarterly subscriptions spiked New Average Order Value to ~$233 in early 2026.
🐻 Bear Case
The company's 'Adjusted Liquidity' of $171M includes $35M in digital assets (Bitcoin) and various escrow amounts. They booked a $9.7M unrealized loss on digital assets this quarter, introducing non-operational volatility.
Selling and Marketing expenses were $16.1M (44% of revenue). The model is heavily dependent on paid acquisition. If CAC rises as they saturate early adopter channels, the path to profitability could lengthen.
⚖️ Verdict: 🟢
Bullish. Prenetics has proven product-market fit with IM8 at a blistering pace. The divestitures have simplified the story and capitalized the balance sheet. While crypto holdings and marketing spend are risks, the growth trajectory and unit economics justify a positive outlook.
Key Themes
IM8: From Zero to Market Leader Speed
IM8 generated $27.4M in Q4 alone, accounting for 75% of total revenue. The brand achieved $120M ARR in 12 months. Management is guiding for $180-200M revenue in FY26. The key driver is the successful expansion beyond the US (60% of revenue is international) and high-profile partnerships (Beckham, Sabalenka).
Unconventional Treasury Management
Prenetics is holding significant Bitcoin on the balance sheet ($35.2M value). While they tout this as 'health and wealth,' it resulted in a $9.7M unrealized fair value loss in Q4. This exposes the stock to crypto beta unrelated to its core health business.
Subscription Mix Shift Boosting Cash Flow
In Jan 2026, IM8 pushed quarterly subscriptions aggressively. The result: New Average Order Value (AOV) jumped from $133 (Q4) to ~$233 (Jan/Feb). This front-loads cash collection, improving working capital and reducing the payback period to 3.5 months.
Strategic Clean-Up Complete
The company completed the divestiture of ACT Genomics ($72M deal), sold Europa ($13M), and sold its Insighta stake to Tencent ($70M). This creates a pure-play consumer health company with a simplified P&L, removing the drag of capital-intensive diagnostics businesses.
Gross Margin Pressure
IM8 gross margin dipped from 62% in Q3 to 60% in Q4, driven by higher international logistics costs during the holidays. While 60% is healthy, the reliance on international markets (shipping to 30+ countries) creates a permanent logistic cost headwind compared to US-domestic peers.
Goodwill Impairment
The company took an $8.2M impairment on the Europa business before divesting it. While this is a non-cash, one-time item related to a now-sold asset, it highlights that previous M&A (Europa) was value-destructive.
Other KPIs
Significantly improved from $(7.6)M in 24Q4. The loss narrowed despite a massive increase in marketing spend ($16.1M vs $1.6M), demonstrating operating leverage. Revenue is scaling faster than expenses.
Stable/High. Management targets 45-50% for FY26 as they push for global expansion. This is an aggressive reinvestment rate typical of early-stage D2C, but leaves little room for error in ad efficiency.
Stable. The legacy business is flat but contributes 83% gross margins, effectively serving as a cash cow to fund IM8's growth.
Guidance
Accelerating. Implies ~200-230% YoY growth for the segment. This target is underpinned by the current $120M ARR run-rate and the full-year impact of recent market launches.
Stable. Management expects losses to remain flat in absolute terms compared to FY25 ($(13)M), despite revenue tripling. This reflects a conscious choice to reinvest gross profit into marketing to capture market share.
Management reaffirmed the target to reach Adjusted EBITDA profitability by late 2027. This signals another 18-24 months of cash burn.
Key Questions
Crypto Treasury Strategy
With a $9.7M unrealized loss in Q4, how does the Board evaluate the risk-adjusted return of holding Bitcoin versus allocating that capital to IM8 inventory or marketing?
International Logistics Margins
With 60% of revenue coming from international markets, how much margin compression are you seeing from shipping/duties, and is the 60% gross margin target sustainable if international mix grows further?
Marketing Efficiency at Scale
You are guiding for marketing spend to rise to 45-50% of revenue in 2026. Does this imply you are seeing CAC degradation as you scale beyond early adopters?